Acacia Pharma lists on Euronext Brussels

 

 

Acacia Pharma to join the largest franchise of Life Science issuers in Europe

Brussels, 5 March 2018 – Euronext today celebrated the listing of Acacia Pharma, a UK-based hospital pharmaceutical company on its Brussels market (Compartment B). This operation demonstrates the benefits offered by Euronext’s European Tech SME initiative as well as the attractiveness of Euronext as the leading venue for Biotech and Pharma companies in Europe. With this operation, Acacia Pharma joins a large franchise of 89 Life Science companies (52 Biotech and 37 Medtech companies) currently listed on Euronext’s markets, representing a total market capitalisation of €23.6 billion.

Acacia Pharma is focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. It has identified important unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.

The Group’s lead project, BAREMSIS® for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies and an NDA has been accepted for filing by the US FDA for marketing approval with a target review date of 5 October 2018. BAREMSIS has the potential to become an important new option for the 16 million surgical patients in the US annually who suffer PONV despite having received prior prophylaxis with standard antiemetics, and in preventing PONV in combination with standard antiemetics in the 18 million patients in the US annually who are at high risk of developing it.

The company’s sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. www.acaciapharma.com   

The proceeds of the Global Offer are expected to allow Acacia Pharma to build the sales and marketing infrastructure and undertake marketing, supply chain and other preparatory activities ready to launch BAREMSIS for the treatment and prevention of PONV, to the hospital market in early 2019 (assuming approval in late 2018). Additionally, the proceeds will be applied to continue the development of APD403for the management of CINV.

With the Offer Price at €3,60 per share, Acacia Pharma’s total offering size amounts to approximately €40 million. With a total of 52,919,061 million shares admitted to trading, Acacia Pharma (ticker: ACPH) has an initial market capitalisation before opening of approximately €190 million.

Dr Julian Gilbert, CEO and founder of Acacia Pharma, said: “The successful completion of our Initial Global Offering is a significant milestone for Acacia Pharma. The new funds provide us with a strong basis from which to build a successful US hospital-focused pharmaceutical business around our two late-stage products, BAREMSIS and APD403, and their potential to improve the lives of millions of patients undergoing surgery or cancer therapy. We are very pleased that our business plan has resonated, and as a result we have added many high-quality investors in the UK, Europe and the US to our shareholder base. Through the successful Global Offer and new listing on Euronext, we believe that Acacia Pharma is now well-positioned to deliver its plans and look forward to the next phase in the company’s development.” 

Bank Degroof Petercam NV/SA and RBC Europe Limited acted as Joint Global Coordinators and Joint Bookrunners in connection with the Global Offer. Bank Degroof Petercam NV/SA acts as Stabilisation Manager on behalf of the Joint Global Coordinators.

To celebrate Acacia Pharma’s first day of conditional trading , Dr Julian Gilbert, CEO and founder of Acacia Pharma, rang the bell to open the markets at Euronext Brussels.

Attachments Beschikbare talen
Download press releaseen

Over EuronextEuronext is de toonaangevende pan-Europese beurs in de Eurozone, bestaande uit Belgie, Frankrijk, Ierland, Nederland, Portugal en de UK. Met 1.300 genoteerde ondernemingen die samen goed zijn voor een beurswaarde van € 3500 miljard per eind mars 2019. Het is een ongeëvenaarde markt op het gebied van blue chips met 24 ondernemingen in de Morningstar® Eurozone 50 Index℠ en een sterk en divers binnenlands en internationaal klantenbestand. Euronext exploiteert gereguleerde en transparante effecten-  en derivatenmarkten. Het totale productaanbod van Euronext omvat aandelen, FX, ETFs, warrants & certificaten, obligaties, derivaten, commodities en indices. Daarnaast zet Euronext haar marktexpertise in door technologie en beheerde diensten aan derden te leveren. Euronext biedt naast haar primaire gereguleerde markt ook Euronext Growth™  en Euronext Access™.
Kijk voor meer actuele informatie op Twitter Euronext of LinkedIn.

Disclaimer
De informatie in dit persbericht is louter informatief en vormt geen  beleggingsadvies. De informatie en het materiaal in deze presentatie worden aangeboden zoals ze zijn, zonder enige waarborg of garantie van welke aard dan ook. Hoewel de nodige aandacht werd besteed aan de opstelling van de inhoud, geeft Euronext geen garantie met betrekking tot de juistheid, geschiktheid of volledigheid van de informatie in deze publicatie. Euronext kan niet aansprakelijk gesteld worden voor enig verlies of schade van welke aard dan ook, voortvloeiend uit het gebruik van, het vertrouwen op of het handelen ten gevolge van de verstrekte informatie. De in deze publicatie verstrekte informatie, of de informatie waarnaar in deze publicatie wordt verwezen, creëert geen rechten of verplichtingen. Het ontstaan van rechten en verplichtingen met betrekking tot financiële producten die worden verhandeld op beurzen die worden geëxploiteerd door dochterondernemingen van Euronext is volledig afhankelijk van de van toepassing zijnde regels van de marktexploitant. Alle eigendomsrechten en belangen met betrekking tot deze publicatie behoren toe aan Euronext.

Dit persbericht is gebaseerd op informatie die tot op heden beschikbaar was. Euronext omvat Euronext N.V. en de aan haar gelieerde ondernemingen. Informatie met betrekking tot merken en intellectuele eigendomsrechten van Euronext is beschikbaar op de volgende website: www.euronext.com/terms-use.

© 2019, Euronext N.V.– Alle rechten voorbehouden.